

Source details

Artificial Cells, Nanomedicine and B Formerly known as: Artificial Cells, Blood Substitutes, and Immobilization Bic Open Access (1)	0,	CiteScore 2021 13.6	Ū
Scopus coverage years: from 2013 to Present		SJR 2021	-
Publisher: Taylor & Francis		0.884	()
ISSN: 2169-1401 E-ISSN: 2169-141X			
Subject area: (Pharmacology, Toxicology and Pharmaceutics: Pharmace	eutical Science) (Medicine: Medicine (miscellaneous))		
	, Genetics and Molecular Biology: Biotechnology)	SNIP 2021 1.188	(i)
	, denetics and molecular biology. Diotechnology	1.100	
Source type: Journal			
View all documents > Set document alert Save to sou	urce list		
CiteScore CiteScore rank & trend Scopus conten	it coverage		
	to articles, reviews, conference papers, book chapters and data nber of publications published in 2018-2021. Learn more >		×
CiteScore 2021 ~	CiteScoreTracker 2022 ^①		
16,291 Citations 2018 - 2021	8,907 Citations to date		
13.6 = 1,199 Documents 2018 - 2021	13.6 = 656 Documents to date		
Calculated on 05 May, 2022	Last updated on 05 September, 2022 • Updated monthly		
CiteScore rank 2021 ①			
Category Rank Percentile			
Pharmacology, Toxicology and #6/171 96th			
Pharmaceutics			
Pharmaceutical Science			
Medicine			
Medicine #10/276 96th (miscellaneous)			
View CiteScore methodology 〉 CiteScore FAQ 〉 Add CiteScore	to your site 🔗		

Q

_

About Scopus

- What is Scopus Content coverage Scopus blog Scopus API Privacy matters

Language

日本語版を表示する **查看简体中文版本** 查看繁體中文版本 Просмотр версии на русском языке

Customer Service


Help Tutorials Contact us

ELSEVIER

Terms and conditions \nearrow $\;$ Privacy policy \nearrow

Copyright \bigcirc Elsevier B.V \neg . All rights reserved. Scopus[®] is a registered trademark of Elsevier B.V. We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies \neg .

RELX




Artificial Cells, Nanomedicine and Biotechnology 8

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
United States Universities and research institutions in United States	Biochemistry, Genetics and Molecular Biology Biotechnology Engineering Biomedical Engineering Medicine Medicine Medicine (miscellaneous) Pharmacology, Toxicology and Pharmaceutics Pharmaceutical Science	Informa Healthcare	57
PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	21691401, 2169141X	2013-2021	Homepage How to publish in this journal IANB-peerreview@journals.tandf.co.uk
IJISAE Scopus Journal			


SCOPE

In 2013, we changed the name of this journal to Artificial Cells, Nanomedicine and Biotechnology . Artificial Cells, Nanomedicine and Biotechnology covers the frontiers of interdisciplinary research and application, combining artificial cells, nanotechnology, nanobiotechnology, biotechnology, molecular biology, bioencapsulation, novel carriers, stem cells and tissue engineering. Emphasis is on basic research, applied research, and clinical and industrial applications of the following topics: -artificial cells -blood substitutes and oxygen therapeutics -nanotechnology, nanobiotechnology, nanobiotechnology, nanomedicine -tissue engineering -stem cells -bioencapsulation -micropencapsulation and nanoencapsulation -microparticles and nanoparticles -liposomes -cell therapy and gene therapy -drug delivery systems -biodegradable and biocompatible polymers for scaffolds and carriers -biosensors -immobilized enzymes and there uses -other biotechnological approaches Rapid progress in modern research cannot be carried out in isolation and is based on the combined use of the different novel approaches, as discussed above, has revolutionized this field resulting in rapid developments. This journal serves to bring these different, modern and futuristic approaches together for the academic, clinical and industrial communities to allow for even greater developments of this highly interdisciplinary area.

 $\ensuremath{\bigcirc}$ Join the conversation about this journal










The users of Scimago Journal & Country kank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.








1 of 44




























Home 🕨 All Journals 🕨	Artificial Cells, Nanomedici	ne, and Biotechnology 🕨 List of Issue	es 🕨 Volume 48, Issue	1
Artificial Ce	ls, Nanomedi	cine, and Biotechr	ology	
		IAIRA IIIR 22/IIIVIODI SIgnan		200
Publish with us Submit an article ~	About this journal 🗸	ua Feng, Qiang Huang, lian-Zhong Den Explore Browse all articles & issues ~	Latest issue	Subscribe Alerts & RSS feed 🗸
1559 6 Views CrossRe	of citations Altmetric			3
Roghayyeh Vaki Mahmoud Reza Pages: 443-451 Published online 6214 58	li-Ghartavol, Amir Abbas Mor Jaafari, Seyed Mahdi Rezayat	magnetic iron oxide nanopai ntazi-Borojeni, Zeynab Vakili-Ghartavo : & Sepideh Arbabi Bidgoli		
/MAPKs and Ying Li, Su Xu, Q Pages: 452-462 Published online	l NF-κB signalling pat ingqing Xu & Yijian Chen	es colonic inflammation thro thway >	ugh the TRIM46/	DUSP1
2337 12 Views CrossRe	ef citations Altmetric			8
glucose-ind signalling 2 Wencui Wan, W Pages: 463-472 Published online 1370 9	uced diabetic retinop	- Ο-β-glucopyranoside exerts athy via regulating lncRNA Ν ng Li, Xuemin Jin, Guangming Wan, Fer	NORAD/miR-125/	'STAT3
Signaling pa Wang Cuiqiong, Pages: 473-478 Published online 1505 3	Ithway > Xu Chao, Fu Xinling & Jiang Y	prosis in rats by targeting mil	R-101-5p through	a the TGF-β




3060	19				
sh with t an art		About this journal 🗸	Explore Browse all articles & issues ~	🖉 Latest issue	Subscribe Alerts & RSS feed
Yan Lia Pages: 5	ffect of ng, Yalin 25-532 ed online 9	, C	the self-assembly of micelles , Zhu Meng, Yanan Meng, Jiping Niu, Yu		argo release >
regula Libin Qi Pages: 5 Publish	non-c ation d iu, Qian 33-541 ed online ical abs	of HIF-1α > Zhao, Lingli Dai, Aoshuang Z 2: 10 Feb 2020	Illeviates hypoxia-caused H9 Zhu, Xiaofei Xu, Shanshan Zhao & Jingch	-	nrough up
in 2D Siukan Pages: 5	acid-n and 3 Law, Alb 42-559 ed online 18	nodified celastrol nat D breast cancer mod ert Wingnang Leung & Chua e: 13 Feb 2020 ef citations Altmetric		cterization, antica	ancer activity
UNWA Atena M Pages: 5	Irst an nted p Jaeimi, S 60-571 ed online 4	d low cost copper Sch blants as a robust ind Gedighe Abbasspour & Seyer at 11 Feb 2020 ef citations Altmetric		o nanocomposite	from

Home 🕨 All Journals 🕨 Artificial Cells, Nanomedicine, and Biotechnology 🕨 List of Issues 🕨 Volume 48, Issue 1
Artificial Cells, Nanomedicine, and Biotechnology
Zheng Ren, Xiaochun Liu, Yaoran Si & Desheng Yang
Publish with usExploreSubscribeSubmit an article ~About this journal ~Browse all articles & issues ~Image: Latest issueAlerts & RSS feed ~
1914 25 Views CrossRef citations Altmetric
Article RETRACTED ARTICLE: Knockdown of hsa_circ_0058124 inhibits the proliferation of human lung cancer cells by up-regulation of miR-1297 > Xiaoliang Li, Qianqian Zhang & Zhigang Yang Pages: 584-593 Published online: 13 Feb 2020
1117 6 Views CrossRef citations Altmetric
Article Circular RNA cZNF292 silence alleviates OGD/R-induced injury through up-regulation of miR-22 in rat neural stem cells (NSCs) > Yaqin Cao, Hui Liu, Jun Zhang & Yubin Dong Pages: 594-601 Published online: 13 Feb 2020 2087 15 Views CrossRef citations Altmetric
Article Protocatechuic aldehyde mitigates hydrogen peroxide-triggered PC12 cell damage by down- regulating MEG3 >
Zhiwei Zhong, Xiaoyuan Yao, Min Luo, Mei Li, Lina Dong, Ziyan Zhang & Rui Jiang Pages: 602-609 Published online: 16 Feb 2020 1774
Views CrossRef citations Altmetric




Home ► All Journals ► Artificial Cells, Nanom Artificial Cells, Nanome		
Zhiming Shen, Wenting Xuan, Huanhua	n Wang, Fei Sun, Chengxin Zhang, Qian Goi	ng & Shenglin Ge
Publish with us Submit an article 🗸 About this journa	Explore I • Browse all articles & issues •	Subscribe Latest issue Alerts & RSS feed 🗸
2030 12 Views CrossRef citations Altmetric		3
	non-coding RNA 91H regulates tumorigenesis in colorectal canc le, Yuqin Pan & Shukui Wang	
2670 19 Views CrossRef citations Altmetric		3
	of silver nanoparticles by <i>Sphing</i> chanisms investigation against o	
Published online: 19 Feb 2020 2217 38 Views CrossRef citations		3
	g nostic value of microRNA-22 in ng Dong, Ze Liu, Jiagan Huang, Yonggang W	•
1713 8 Views CrossRef citations		8
	fylline against lipopolysaccharid liated by SIRT1 in human pulmo	les (LPS)-induced activation of onary bronchial epithelial cells >
Peng Jiao, Weiming Li, Lin Shen, Yan Li, Pages: 687-694 Published online: 25 Feb 2020	Lili Yu & Zhaohui Liu	
2369 11 Views CrossRef citations Altmetric		3





activ	vation >		, mix 100/111010 axis and 115		-
blish wi		di ta ta sama al	Explore	┛ Latest issue	Subscribe
omit an ai 1229		this journal 🛩	Browse all articles & issues 🛩		Alerts & RSS feed
Views	CrossRef citations	Altmetric			
					6
_					
	ession of Concerr cession of Conc e		ncoding RNA SNHG15 enhance	es the development	t of colorectal
			RNA through miR-141/SIRT1/		
Page: Page:	709 : hed online: 17 Mar 20	120			
941	1				
Views	CrossRef citations	Altmetric			
					a
()	ession of Concerr				
-		· · · · · · · · · · · · · · · · · · ·	hinders choriocarcinoma cell į ng noncoding RNA-CHRF 🔉	proliferation, migr	ation and
Page:	0				
-	hed online: 17 Mar 20)20			
669	0				
Views	CrossRef citations	Altmetric			
					6
- Event					
/ \ ·	ession of Concerr cession of Conc e		ression of IncRNA ANRIL aggr	avated hydrogen p	eroxide-
-	1		inhibiting miR-499a/PDCD4 a	xis-mediated PI3	K/AKT
	OR/p70S6K patl	hway >			
Page: Publis	hed online: 17 Mar 20)20			
960	0				
Views	CrossRef citations	Altmetric			
					3
· · ·	ession of Concerr			·	
💛 Expi			ts as an oncogene through act hepatocellular carcinoma cells	· · · · · · · · · · · · · · · · · · ·	MEK/ERK and
-	-			*	
-					
JAK Page:	hed online: 17 Mar 20)20			
JAK Page:	hed online: 17 Mar 20	Altmetric			


псысе	ls. Nanomed	licine, and Biotech	nology	e 1
			101089	
sh with us	About this journal 🗸	Explore Browse all articles & issues ~	Latest issue	Subscribe Alerts & RSS f
views Crosske	r citations Aitmetric			
VRK1-media Page: 714 Published online 648 0	of Concern: Ras-PI3 ated H2A phosphoryl	K pathway promotes osteosarco lation at threonine 120 >	oma progression v	ia regulating
Expression of	Concern			
-	reperfusion-induced	aria barbata D. Don (SBD) prote injuries of PC12 cells by up-reg		е
656 1 Views CrossRe	f citations Altmetric			
-	of Concern: Shikonii NCI-N87 cells via in	n inhibits proliferation, migratio hibition of PI3K/AKT signal pa		romotes
716 0 Views CrossRe	f citations Altmetric			
	of Concern: <i>Upregul</i> geal carcinoma via m	ation of lncRNA HAGLROS enh odulating miR-100/ATG14 axis		
867 1				





Home	 All Journals 	 Artificial Cells, Nanome 	dicine, and Biotechnology 🕨 List of Issu	es 🕨 Volume 48, Issu	e 1			
Arti	Artificial Cells, Nanomedicine, and Biotechnology							
	Expression of concern: Involvement of NORAD/miR-608/STAT3 axis in carcinostasis effects							
	sh with us t an article 🗸	About this journal	Explore • Browse all articles & issues •	Latest issue	Subscribe Alerts & RSS feed ~			
	Article RETRACTE using polyn	meric nanoparticles Rizwan Ahmad, Mortaja Za	parative pulmonary pharmacok targeted to the lungs in treatn ıki Almakhamel, Khalid Ansari, Mohd Amir	nent of asthma >				
	Article	Ref citations Altmetric	A <i>CASC15</i> promotes tumour pr	ograssian through	eh SOV4/Mint/B			
	catenin sig	nalling pathway in I ıg, Hao Zi, Yang Wang, Binş	hepatocellular carcinoma >					
	1510 13 Views CrossF	Ref citations Altmetric			<u>a</u>			
	labelling >	eni, Sima Shojaei, Bita Meh	es as a non-invasive probe for i ravi & Elham Mohammadi	mesenchymal ste	m cell			
	2003 7	Ref citations Altmetric			8			
	peptide Co		nanoparticles by <i>Gluconacetob</i> e and anti-inflammatory effect					
	Ying Liu, Hariba Kim Pages: 777-788	alan Perumalsamy, Chang	Ho Kang, Seung Hyun Kim, Jae-Sam Hwar	ng, Sung-Cheol Koh, Tae	e-Hoo Yi & Yeon-Ju			


















Page: 998 Published on	line: 21 Oct 202	20			
h with us an article		this journal 🗸	Explore Browse all articles & issues 🗸	Latest issue	Subscribe Alerts & RSS feed
of intract Guojia Du, D Pages: 999-10 Published on 1877 1	c <mark>anial aneu</mark> Dangmurenjiaf	Irysm based c u Geng, Kai Zhou,	athways, genes and circulatin on weighted gene co-expressi Yandong Fan, Riqing Su, Qingjiu Zhou,	on network analy	vsis »
Page: 1008 Published on 546 0	nt of Retrac				3
483 0		20 Altmetric			6
treatment Chao Huang Pages: 1010-1 Published on 1803 10	t of brachi , Chuan Fu, Zh 021 Iline: 01 Jul 2020	al plexus avu	y thermo-sensitive PLGA-PE lsion ≯ i Guo, Di You, Rui Li & Zhe Zhu	G-PLGA hydrogel	s for the











934 7 Views CrossRe	f citations Altmetric			
iblish with us bmit an article •	f citations Altmetric About this journal ~	Explore Browse all articles & issues ~	Latest issue	Subscribe Alerts & RSS feed
phototherm Sungsu Lee, Gay Pages: 1144-1152 Published online 1213 6	al therapy > young Jo, Jin Seok Jung, Dae	san oligosaccharide lactate fo Hyeok Yang & Hoon Hyun	r targeted cancer	• imaging and
antibacteria Shuang Wu, Sha Pages: 1153-1158 Published online 7764 34	Il activity against uri Inmugam Rajeshkumar, Mal	particles using <i>Cissus vitiginea</i> nary tract infection pathogen: lini Madasamy & Vanaja Mahendran		ant and
	promotes secretion or riginated from adult	of wound healing related grow and fetal tissues >	rth factors of me	senchymal
Made Inten Lest Pages: 1159-1166 Published online 1906 4	ari & Fedik A. Rantam	anes Widodo Wirohadidjojo, Evelyn Kon	naratih, Nurwasis, Aris	tika Dinaryati, Ni
Article Study of tiss HLC-I scaffe	sue engineered vascu old <i>in vitro</i> and <i>in vivo</i> iao Chen, Yanling Qiu, He Ch	I larised oral mucosa-like struc ♪ ♪ Þen, Yaoqiang Liu, Yali Hou, Minhai Nie 8		a CVM-0.25%
1015 1 Views CrossRe	0 Altmetric			



























Explore articles

Latest	Most read	Most cited	Trending
Expression of Concern	>		
Expression of Concern Publishe	d online: 28 Jul 2022		6
Expression of Concern	>		
Expression of Concern Publishe			a
Europeanies of Concern	×		
Expression of Concern	>		
Expression of Concern Publishe	d online: 27 Jul 2022		6
Expression of Concern	>		
Expression of Concern Publishe			a





Editorial board

Co-Editor-in-chief

RDK Misra, University of Texas at El Paso, USA Wojciech Chrzanowski, University of Sydney, Australia

Reviews Editor Paul Roach, Loughborough University, UK

Emeritus Editor

Thomas M. S. Chang - Director, Artificial Cells and Organs Research Centre and Emeritus Professor of Physiology, Medicine and Biomedical Engineering, Faculty of Medicine, McGill University, Montreal, Quebec, Canada

Associate editors

Ramesh Chandra - University of Delhi, Delhi, India Dror Fixler - Bar-Ilan University, Ramat Gan, Israel Rania Hathout, Ain Shams University, Cairo, Egypt


Home
All Journals
Artificial Cells, Nanomedicine, and Biotechnology
Editorial Board Artificial Cells, Nanomedicine, and Biotechnology Satya Prakash - Biomedical Engineering, McGill University, Montreal, Quebec, Canada Publish with us Explore Subscribe Latest issue Submit an article 🛩 Browse all articles & issues ~ Alerts & RSS feed 🛩 About this journal ~ Veena Agrawal - University of Delhi, New Delhi, India Bilal Ahmed - Yeungnam University, Gyeongsan, Korea (the Republic of) Muhammad Sajid Hamid Akash - Department of Pharmaceutical Chemistry, Government College University, Faisalabad, Pakistan Zahra Allahyari - Rochester Institute of Technology, Rochester, NY, USA Mh Busra Fauzi - Centre for Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia Anisoara Cimpean - Faculty of Biology, University of Bucharest, Bucharest, Romania Daniele Di Mascolo - Fondazione Istituto, Italiano di Technologia, Geova, Italy Leticia Hosta-Rigau - Technical University of Denmark, Kongens Lyngby, Denmark Doğa Kavaz - Cyprus International University, North Nicosia, Cyprus Peter E Keipert - Alliance Pharmaceutical Corp, San Diego, CA, USA John F Kennedy – Chembiotech Laboratories, Bromsgrove, England, UK Ján Kozempel - Czech Technical University in Prague, Prague, Czech Republic Sathish Sundar Dhilip Kumar - University of Johannesburg, Johannesburg, South Africa Jui-Yang Lai - Chang Gung University, Taoyuan City, Taiwan Vuanghao Lim - Universiti Sains Malaysia, Penang, Malaysia Pasquale Marrazzo - University of Bologna, Bologna, Italy Shadab Md - King Abdulaziz University, Jeddah, Saudi Arabia Arokia Vijaya Anand Mariadoss - Hallym University Dongtan Sacred Heart Hospital, Suwon, Korea (the Republic of) Nicole Remaliah Sibuyi - University of the Western Cape, Bellville, South Africa Ghassan Mohammad Sulaiman - University of Technology, Baghdad, Iraq Wei Tao - Harvard Medical School, Boston, MA, USA Paul De Vos - University Center Groningen (UMCG), Groningen, The Netherlands

Social Media Editor

Matthew Hadden - University of Sydney, Australia

Journal Editorial Office Support: IANB-peerreview@journals.tandf.co.uk









Artificial Cells, Nanomedicine, and Biotechnology

An International Journal

ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ianb20

Resveratrol promotes secretion of wound healing related growth factors of mesenchymal stem cells originated from adult and fetal tissues

Cita R. S. Prakoeswa, Yuyun Rindiastuti, Yohanes Widodo Wirohadidjojo, Evelyn Komaratih, Nurwasis, Aristika Dinaryati, Ni Made Inten Lestari & Fedik A. Rantam

To cite this article: Cita R. S. Prakoeswa, Yuyun Rindiastuti, Yohanes Widodo Wirohadidjojo, Evelyn Komaratih, Nurwasis, Aristika Dinaryati, Ni Made Inten Lestari & Fedik A. Rantam (2020) Resveratrol promotes secretion of wound healing related growth factors of mesenchymal stem cells originated from adult and fetal tissues, Artificial Cells, Nanomedicine, and Biotechnology, 48:1, 1159-1166, DOI: <u>10.1080/21691401.2020.1817057</u>

To link to this article: <u>https://doi.org/10.1080/21691401.2020.1817057</u>

9	© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group	Published online: 09 Sep 2020.
	Submit your article to this journal 🕻	Article views: 1906
۵	View related articles 🗷	View Crossmark data 🗹
ආ	Citing articles: 4 View citing articles 🗹	

Taylor & Francis Taylor & Francis Group

OPEN ACCESS Check for updates

Resveratrol promotes secretion of wound healing related growth factors of mesenchymal stem cells originated from adult and fetal tissues

Cita R. S. Prakoeswa^a, Yuyun Rindiastuti^b, Yohanes Widodo Wirohadidjojo^c, Evelyn Komaratih^b, Nurwasis^b, Aristika Dinaryati^d, Ni Made Inten Lestari^a and Fedik A. Rantam^d

^aDepartment of Dermatovenerology, Faculty of Medicine Universitas Airlangga/Dr Soetomo, General Academic Hospital, Surabaya, Indonesia; ^bDepartment of Ophthalmology, Faculty of Medicine Universitas Airlangga/Dr Soetomo, General Academic Hospital, Surabaya, Indonesia; ^cDepartment of Dermatovenerology, Faculty of Medicine Universitas Gadjah Mada/Dr Sardjito, General Academic Hospital, Yogyakarta, Indonesia; ^dStem Cell Research and Development Center, Universitas Airlangga, Surabaya, Indonesia

ABSTRACT

Non-healing wounds have demonstrated aberrant regulation of several growth factors, thus using exogenous growth factors and cytokines in the clinical setting may improve the outcomes of non-healing wounds. Mesenchymal stem cells (MSCs) are the source of growth factors that show beneficial effect in promoting impaired wound healing. Certain culture condition should be developed to stimulate growth factor secretion from stem cell. Resveratrol, a small molecule found to increase MSCs therapeutic effectiveness. This study aims to investigate the effect of RV on secretion of wound healing related growth factors. We isolated and characterised MSCs from wharton's jelly (WJ), amniotic membrane (AM), and adipose tissue. We treated MSCs with serum deprived medium (SDM) supplemented with RV at 0.1 μ M, 0.5 μ M, 0.8 μ M concentration. Our study revealed that RV at 0.1 μ M was more effective to increase cell proliferation rate. Resveratrol at 0.1 μ M promoted EGF, HGF, PDGF, and TGF- β 1 secretion from MSCs. AD-MSCs showed the greatest response to RV stimulation in the term of cell proliferation and growth factors secretion. As conclusion, RV can facilitate cell proliferation and wound healing related growth factors secretion at dosage dependent manner.

Introduction

Million people are affected by acute and chronic wounds as a result of surgeries, burns, infections, pressure ulcers, as well as diabetic and venous ulcers. However, chronic wounds possess a significant health burden [1–4]. Wound healing is a complex biological process that involves interaction between cellular components, cytokines, growth factors, and extracellular matrix. It is generally divided into three phase: inflammation, proliferation, and remodelling [5]. Numerous growth factors and their receptors are altered during wound healing phase, including platelet derived growth factor (PDGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor (TGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and keratinocyte growth factor (KGF) [6–8].

In vivo and in vitro studies analysing non-healing acute and chronic wounds have demonstrated aberrant regulation of several growth factors suggesting a potential target for therapy. It has led to a robust interest in using exogenous growth factors and cytokines in the clinical setting to improve the outcomes of non-healing wounds [9]. In recent years, many animal studies have demonstrated a promising use of growth factors to promote impaired wound. This led **ARTICLE HISTORY**

Received 30 October 2019 Revised 6 May 2020 Accepted 24 May 2020

KEYWORDS Wound healing; stem cell; resveratrol; secretome

to the hope that the application of exogenous growth factors may be used clinically to promote wound healing process. PDGF-BB is the only growth factor approved by the US Food and Drug administration (FDA) for clinical use, however, due to its high cost the use of PDGF-BB especially in a developing country is still debatable. Stimulation of wound healing needs crosstalk of many growth factors, hence introduction of single growth factor seems to be inadequate [5,8,10,11]. Regardless of the different growth factors therapeutic approach targeting wound healing enhancement, the search towards source of growth factors is still being explored [6–8].

Mesenchymal stem cells (MSCs) are multipotent cells derived from a variety of tissues including bone marrow, adipose tissues, umbilical cord, and amniotic membrane. Recent studies proved that MSCs stimulated human dermal fibroblast (HDFs) *via* paracrine effects and enhanced cutaneous wound healing. MSCs secrete many cytokines and growth factors which are important in cell growth and maintaining skin tissues [4,12]. Several attempts have been tried to stimulate specific growth factors released by MSCs, such as manipulating culture condition by hypoxic condition, 3D culture system, and small molecule supplementation. Resveratrol (RV, 3,5,49 – hydroxystilbene) is a small molecule, naturally

CONTACT Cita R. S. Prakoeswa 🖾 cita-rosita@fk.unair.ac.id 🗈 Department of Dermatovenerology, Faculty of Medicine Universitas Airlangga/Dr Soetomo, General Academic Hospital, Surabaya 60131, Indonesia

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

occurring product found in a number of plants. Numerous studies have shown that RV possesses a wide range of biological effects that could beneficial for human health. One potential cell target for RV through oral or intravenous injection is the adult stem cells residing in different tissues and organs. Several studies within the last few years have reported the beneficial effects of RV on behaviour of various stem cells. However, limited studies have examined the effect of RV on stem cell behaviour especially in cell secretion products [13,14]. In this study, we hypothesised that RV could induce MSCs to secrete wound healing related growth factors.

Materials and methods

Materials

The main reagents included Type IV collagenase (Roche USA), Type II collagenase (Roche USA), alpha modified eagle medium (α -MEM, Gibco-Life Technologies, USA), dulbecco's modified eagle's medium (DMEM, Gibco-Life Technologies, USA), nonessential amino acid (NEAA, Sigma, USA), Trypsin-EDTA (Gibco – Life Technologies, USA), foetal bovine serum (FBS, Biowest, USA), resveratrol (Sigma, USA), bFGF (Gibco-Life Technologies, USA), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphyniltetrazolium bromide (MTT; Gibco- Life Technologies, USA). Antibodies for flowcytometry CD 105, CD 90, CD 73, CD 34, CD 133, and CD 45 were purchased from BD bioscience (US). Human PDGF-B, TGF- β 1, VEGF-A, EGF, and HGF ELISA kit from Bioassay Technology Laboratory, China.

Methods

This is an *in vitro* study to investigate the effect of various doses of RV on wharton's jelly MSCs (WJ-MSCs), amniotic membrane MSCs (AM-MSCs), and adipose derived MSCs (AD-MSCs) secretion, mainly for PDGF-B, TGF- β 1, EGF, HGF, and VEGF-A levels. All experiments were conformed to institutional ethics review board from dr. Soetomo General Academic Hospital (Registered number: 1293/KEPK/VII/2019). This study was conducted at Stem Cell Research and Development Centre, Universitas Airlangga.

Cell isolation

Wharton's jelly and amniotic membrane MSCs isolation

Wharton's jelly MSCs and AM-MSCs were isolated from single donor of placenta, obtained from healthy full-term baby through caesarian section under aseptic technique. Umbilical cord in 3 cm length and amnion membrane were collected after the mothers have consented. Wharton's jelly MSCs and AM-MSCs were isolated using mixed enzymatic-explant method based on protocol developed by Azendeh et al. [15] with our modification. Briefly, blood vessels were removed to allow only the WJ and AM to come into direct contact with the enzymatic solution. Wharton's jelly and AM were minced into approximately 1 cm³ pieces and washed with PBS. Each tissue was then placed in sterile tube containing α -MEM

medium with enzymatic cocktail comprising 0.75 mg/ml Collagenase Type IV and incubated at 37 °C for 30–60 min with gentle agitation. After the incubation period, the tissue pieces were washed with culture media and transferred to a new sterile tube and centrifuged at 300 g for 5 min. Supernatant was discarded and cell pellets resuspended in culture medium composed of α -MEM, 1% penicillinstreptomycin, 1% amphotericin B, 1% NEAA, 5% FBS, and bFGF 5 ng/mL for WJ-MSCs and DMEM-F12, 1% penicillinstreptomycin, 1% amphotericin B, 1% NEAA, 5% FBS, and bFGF 5 ng/mL for AM-MSCs. Cells and remaining small pieces of tissue were cultured with culture media in incubator at 37 °C and 5% CO₂. Culture media were changed every 3 days until 90% confluency was reached, then passaged using warm trypsination method.

Adipose derived MSCs isolation

Adipose derived MSCs were isolated from single donor of adipose tissue, obtained from healthy 27 year-old-woman under aseptic technique. Adipose tissue in 2×2 cm of size was collected after assignment of informed consent. Adipose derived MSCs were isolated using enzymatic method based on protocol developed by Palumbo et al. [16] with our modification. Briefly, adipose tissue was minced into approximately 1 cm³ pieces and washed with PBS. Adipose tissue was then placed in sterile tube containing α -MEM medium with enzymatic cocktail comprising 0.075% Collagenase Type I and incubated at 37 °C for 30–60 min. After the incubation period, the digested tissues were washed with culture media and transferred to a new sterile tube and centrifuged at 300 g for 5 min. Supernatant was discarded and cell pellets resuspended in culture medium composed of α -MEM, 1% penicillin-streptomycin, 1% amphotericin B, 1% NEAA, 5% FBS, and bFGF 5 ng/mL then stored in incubator at 37 °C and 5% CO₂. Culture media were changed every 3 days until 90% confluency was reached, then passaged using warm trypsination method.

Cell characterization

Flow cytometry was used to assess the surface marker of MSCs, using the standard for MSC as described by the International Society for Cellular Therapy (ISCT). Cells (P2-3) were harvested, pelleted and resuspended in 1% bovine serum albumin (BSA in PBS), and counted. Each population cells were used for flow cytometry. Cells were stained with directly PE (phycoerythrin) conjugated antibodies against CD73, CD90, CD105, and CD45 (BD bioscience, US). Cells were analysed on FACS calibur flow cytometry using FACSDiva Software (BD bioscience, US).

Secretome production using resveratrol preconditioning

Amount of 5×10^3 cells/well of WJ-MSCs, AM-MSCs, and AD-MSCs at passage 4 were cultured in each 96 multiwell plate with culture media for 24 h to reach 70% confluency. A day later, the cells were treated using media composed of α -MEM, 1% penicillin-streptomycin, 1% amphotericin B, 1% NEAA, and 2% FBS supplemented with various doses of RV. We divided into three groups of RV supplementation dose that consist of 0.1 μ M, 0.5 μ M, and 0.8 μ M. For control group, we used culture media in serum deprivation condition (SDM) containing 2% FBS. Cell secretome was collected after 48 h of treatment and filtered using 0.45um millipore. The cell secretome then stored at -80 °C until further analysis. All of the experiment groups were conducted in 4 replications.

Cell viability

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphyniltetrazolium bromide assay were conducted to determine the effect of RV at various dose on cell viability. After 48 h of resveratrol preconditioning, 10 µl of 0.45 mg/mL tetrazolium solution was added to each well and incubate at 37 °C for 4 h. After incubation, 100 µl of solubilisation solution were added to dissolve the formazan crystals. The plate then immediately analysed using microplate reader at absorbance of 570 nm.

Growth factor measurement

Growth factor measurement was conducted to determine the effect of RV at various doses which in the concentration of PDGF-B, TGF- β 1, EGF, VEGF, and HGF. Enzyme-linked immunosorbent assay was performed according to Bioassay Technology Laboratory protocol. Briefly, cell supernatants were collected and centrifuged at 3000 rpm for 20 min. Amount of 40 µl of supernatants were placed into ELISA well plate. Biotinylated antibody and streptavidin HRP were added, then sample were incubated at 37 °C for 60 min. Samples were washed 3x with washing buffer, then solution A and B were added and incubated at 37 °C for 10 min. Stop solution was added and plate was read immediately using microplate reader at absorbance of 450 nm.

Statistical analysis

The data of cell viability and growth factor level were presented in mean \pm standard deviation. Difference of cell viability among groups was analysed with ANOVA and Post-hoc Tukey using SPSS software version 19.0, p < .05 considered to be statistically significant.

Results

Cell isolation and characterisation

We successfully isolated WJ-MSCs, AM-MSCs, and AD-MSCs which fulfilled The International Society for Cellular Therapy criteria for MSCs such as fibroblast-like morphology appearance (Figure 1), adhere to culture dishes, and positive expression for surface marker of MSCs. Flowcytometry of cell populations at passage 3 indicated positive expression for CD 105, CD 90, and CD 73 FITC antibody but negative for CD 34, and CD 45 antibody as depicted in Figure 2. Identification of CD73 and CD90 within gate R3 showed subset of positive cells in amniotic membrane (87.42% and 92.36%), wharton's jelly (87.41% and 89.2%), adipose tissue (89.46% and 91.2%). Identification of CD105 within gate R5 showed subset of positive cells in amniotic membrane 67.42%, wharton's jelly 59.2%, adipose tissue 61.2%. Identification of CD34 and CD45 within gate R4 showed subset of positive cells in amniotic membrane (15.2% and 8,36%), wharton's jelly (17.1% and 9.2%), adipose tissue (16.16% and 10.2%).

Resveratrol exerts dosage-dependent effect of MSCs proliferation

During 48 h culture of WJ-MSCs, AM-MSCs, and AD-MSCs, it was visually noted that cells treated with 0.1 μ M RV expand faster than cells treated with serum deprivation media (SDM) and higher concentrations of RV, respectively. Figure 3 shows that while 0.1 μ M RV seemed to provide the best growth advantage over SDM treated cells. AD-MSCs showed the highest proliferation rate in response to 0.1 μ M RV treatment compared to AM-MSCs and WJ-MSCs. However, higher RV concentrations showed slight growth advantage over SDM treated cells.

Resveratrol stimulate growth factors secretion from MSCs at dosage dependent manner

To determine the effect of resveratrol on MSCs secretion, we collect the cell supernatant after 48 h of RV treatment and measured the growth factors concentration using direct ELISA. Enzyme linked immunosorbent assay showed that the




Figure 1. Fibroblast like morphology of MSCs derived from (a) wharton's jelly, (b) amniotic membrane, (c) adipose tissue, cells at passage-3 with 90% confluency (Inverted microscope, 100x magnification).





Figure 2. Identification of small CD73, CD90, CD105, CD45, CD34 cell population derived from human amniotic membrane (a), wharton's jelly (e), and adipose tissue (i) that behave as MSCs in culture using flowcytometry. Using a five-antibody/viability marker panel, we identified a subset of small cells that were positive for CD73, CD90, CD105. (a,e,i) cells were initially displayed on SSC density plot (R2), which was subgated onto antigen plot (b,f,j) for identification of CD73 CD90 (gate R3), (c,g,k) subset of small cells were further subgated and negative for CD34 CD45 (R4) cells were further subgated to display cluster of CD105 (gate R5) (d,h,l).



The effect of RV on proliferation rate of MSC

Figure 3. Resveratrol exerts dosage dependent effect on the proliferation rate of MSCs. Cells were plated at equal density and cultured in different concentrations of resveratrol for 48 h and assessed using MTT assay. Blue bar: AD-MSCs, red bar: AM-MSCs, yellow bar: WJ-MSCs, Error bars represent standard deviation (four replications in each treatment condition; SDM: serum deprived media). *ANOVA, post-hoc Tukey, p < .05 compared to SDM treated cells.


concentration of PDGF-B, TGF- β 1, EGF, HGF, and VEGF in cell supernatant are varied among RV treatment (Table 1). Figure 4 reveals stimulation effect of RV on growth factors secretion compared to SDM treated cells.

 $0.1 \,\mu$ M RV significantly promoted EGF, HGF, PDGF-B, and TGF- β 1 from WJ-MSCs (p < .01). At $0.1 \,\mu$ M, RV promoted EGF and HGF secretion from AM-MSCs (p < .01). The highest level of PDGF and TGF- β 1 secretion form AM-MSCs was found at

Table 1. Resveratrol induce secretion of wound healing related growth factors at dosage dependent.

		5 5	•		
GROUP	TGF-β level (pg/mL)	PDGF level (pg/mL)	VEGF-A level (pg/mL)	EGF level (pg/mL)	HGF level (pg/mL)
AD-MSC secretome 0.1 µM RV	939.81 ± 47.75	4392.50 ± 202.11	61.25 ± 11.08	332.34 ± 34.94	1098.70 ± 177.90
AD-MSC secretome 0.5 µM RV	836.06 ± 98.36	3682.50 ± 103.40	150.0 ± 20.41	242.25 ± 38.17	487.02 ± 123.68
AD-MSC secretome 0.8 μ M RV	698.31 ± 103.42	3809.20 ± 504.65	142.50 ± 38.62	240.33 ± 44.10	396.47 ± 46.67
SD AD-MSC secretome	944.40 ± 80.49	3550.40 ± 932.66	954.50 ± 55.74	141.67 ± 34.63	232.92 ± 37.61
AM-MSC secretome 0.1 µM	957.44 ± 69.1	3863.50 ± 364.77	72.50 ± 12.58	412.50 ± 56.78	1037.23 ± 156.49
AM-MSC secretome 0.5 µM	610.56 ± 100.40	3250.09 ± 161.76	217.50 ± 29.86	182.25 ± 62.04	680.67 ± 116.89
AM-MSC secretome 0.8 µM	698.31 ± 13.20	4528.50 ± 421.82	130.0 ± 25.81	135.0 ± 26.45	493.0 ± 76.81
SD AM-MSC secretome	984.25 ± 12.03	4201.60 ± 604.18	959.0 ± 199.54	71.44 ± 19.21	255.44 ± 30.60
WJ-MSC secretome 0.1 µM RV	1201.70 ± 240.38	6037.60 ± 578.96	50.0 ± 21.21	80.08 ± 17.36	132.50 ± 25.0
WJ-MSC secretome 0.5 µM RV	1047.90 ± 212.12	5231.30 ± 617.17	65.0 ± 81.64	16.25 ± 8.53	70.41 ± 13.95
WJ-MSC secretome 0.8 µM RV	806.75 ± 172.53	4003.80 ± 470.09	410.0 ± 106.03	14.75 ± 8.13	240.50 ± 57.68
SD WJ-MSC secretome	699.50 ± 143.84	2847.80 ± 324.64	247.50 ± 42.72	9.75 ± 3.86	188.44 ± 54.33

SD: serum deprivation.



Dose dependent effect of RV compared to SDM

Figure 4. Resveratrol exerts dosage dependent effect on growth factors secretion of MSCs. Cells were plated at equal density and cultured in different concentrations of resveratrol and cell secretome was collected after 48 h and assessed using ELISA. Error bars represent standard deviation (four replications in each treatment condition; SD: serum deprivation).

 $0.8 \,\mu$ M RV and SDM treatment, respectively, however it was insignificant compared to $0.1 \,\mu$ M RV treated group (PDGF, p = .67 and TGF- β 1, p = .984). In AD-MSCs culture, RV at $0.1 \,\mu$ M induced significant increment of EGF, HGF, and PDGF (p < .01) compared to SDM treated cells. We found that treated AD-MSCs with SDM showed highest level of TGF- β 1 yet not significant compared to $0.1 \,\mu$ M treatment (p = .94). However, the highest level of VEGF secretion from WJ-MSCs,

AD-MSCs, and AM-MSCs was found in SDM treated cell (p < .01).

Discussion

Our study revealed distinct and dynamic actions on selfrenewal of MSCs originated from adult and foetal tissues stimulated by different concentrations of RV, as compared to a previous study. We found that RV at lower dose $(0.1 \,\mu\text{M})$ is more effective to increase cell proliferation rate, while higher concentration (0.5 μ M and 0.8 μ M) showed slight effect on cell proliferation. This result is in line with study demonstrating by Peltz et al. [13] which showed that resveratrol is the most beneficial to stem cell development at 0.1 µM. In another study, Komaratih et al. showed that the highest proliferation rate of WJ-MSCs was reached with 0.1 µM RV supplementation [17]. Increased cell proliferation rate would suggest increased representation of S and/or G2/M phase cells in RV treated cells. Peltz et al. demonstrated that at low concentration (0.1 µM), RV promotes self-renewal of AD-MSCs by reducing cell senescence rate and increasing cell proliferation rate as well as reducing cell population doubling time. However, at high concentrations, RV inhibits self-renewal of AD-MSCs by significantly increasing cell senescence rate and cell population doubling time [13]. Yoon et al. showed that RV (0.1 and $1 \mu M$) promoted silent information regulator (SIRT1) activation by suppressing SOX2 acetylation which contributing in cell self-renewal, multipotency, and differentiation [18]. On the other hand, the study recently indicated that RV at higher concentration (50 µM) could stimulate cell proliferation of human embryonic stem cells (ESCs) through cell cycle modulation and enhancement in expression of antiapoptotic markers [14,19]. Our study revealed that at 0.1 µM concentration, RV exerts the optimal effect in promoting cell proliferation rate in MSCs derived from WJ, AM, and adipose origin. However, the mechanism underlying the biphasic dose response on the regulation of cell proliferation is unclear and would be a great interest for future studies.

Research which was conducted by Kim et al. reported that umbilical cord stem cells conditioned media (UCS-CM) secreted EGF, bFGF, HGF, and PDGF in high amount [12]. In addition, human dermal fibroblasts (HDFs) showed higher proliferation rate and collagen I production when was cultured in USC-CM than ADCS-CM. Other studies have shown that WJ-MSCs can improve the microcirculation and microenvironment significantly through therapeutic paracrine effects in a radiation rat model [12,20]. Sun et al. reported that WJ-MSCs CM promoted wound healing with smaller scar formation in radiation-induced skin wound rat [21]. Natallya et al. demonstrated complete healing in 72.7% subjects with chronic plantar ulcer related to leprosy after topical application of human AM-MSC secretome gel within 2 months period [4]. However, the limited survival of transplanted MSCs reduces the therapeutic effectiveness of MSCs [22]. Hence, strategies must be developed to improve the clinical effectiveness of MSCs. One of the common strategies that improve the therapeutic effects of stem cell transplantation is preconditioned stem cells with small molecules. Small molecule drugs have a protuberant beneficial effects compared to genetic manipulation, as it can be optimised by adjusting their concentration, duration time of exposure, and composition [23]. Resveratrol generally known as a small molecule which promoted MSCs proliferation, maintained differentiation, and delayed MSCs senescence [13,18,19,24]. In this study, we adopted strategy of preconditioning MSCs with RV at various concentrations to promote secretion of wound healing related growth factors as the candidate for cell-free

based therapy instead of cell therapy itself. Our study found that RV at 0.1 μ M could promote secretion of EGF, HGF, PDGF, and TGF- β 1 from WJ-MSCs, however, those levels of growth factors were lower compared to AM-MSCs and AD-MSCs. We found that 0.1 μ M is the most effective dose of RV to stimulate EGF, HGF, PDGF, and TGF- β 1 from AM-MSCs and AD-MSCs. Our study revealed that AD-MSCs showed the greatest response to RV stimulation in the term of cell proliferation and growth factor secretion. However, AM-MSCs also showed a good response to RV stimulation.

Various types of growth factors play an essential role in the complex process of wound healing and tissue regeneration [2,5,9]. We found that RV, however, increases secretion of growth factors at dosage-dependent manner and tissuespecific origin of MSCs. However, the pathways that may contribute to this effect have yet to be confirmed in this study. Epidermal growth factor, a 6-kDa molecule was obtained in relative low concentration while MSCs cultured in standard culture condition. We found that RV could increase EGF secretion from MSCs. Epidermal growth factor plays important role in completing wound healing process through increasing the rate of epithelialization and reducing the scar formation by preventing excessive wound contraction. Epidermal growth factor coated wound dressing applied to full-thickness skin wound of rabbit resulted in almost normal histological appearance and faster wound healing [9,25,26]. We found the lowest secretion of VEGF while MSCs was treated with lower dose of RV (0.1 µM). Vascular endothelial growth factor a homodimeric 34-46 kDa heparin-bindingglycoprotein, seems to be the strongest stimulation of angiogenesis during wound healing process. However, we found that RV could promote HGF secretion from MSCs in high amount of concentration [27]. Hepatocyte growth factor has a main role in regulating cell growth, motility and morphogenesis in cells such as epithelial and endothelial cells. Thus, it is directly related to epithelial repair, granulation tissue formation and neovascularization. Additionally, a synergistic effect between HGF and VEGF over endothelial cells has been demonstrated providing a more intense angiogenic effect at the wound area [8,9,28,29].

Our study showed that 0.1 µM RV was the most effective concentration to promote the secretion of wound healing related growth factors. SIRT1 is thought to be critical players in prolonging life span that consistently demonstrated altered expression in response to RV at $0.1 \,\mu$ M. Downregulation of SIRT1 was found with the treatment of RV at concentration greater than 0.1 µM. The relative changes correlate to higher senescence rate and percentage of S phase cells in response to high concentration resveratrol treatment. Thus, we assumed that in senescence condition and entering of S phase, cells will decrease the secretion of wound healing related growth factors and other developmental growth factors. Taken together, SIRT1 is involved in wound healing processes and its activation provides an approach for acceleration of wound therapy. Although the studies of SIRT1 regulating wound healing related growth factor have not been reported, studies of SIRT1 regulating VEGF and IGF have been reported [28-30].

Our study revealed that RV could enhance PDGF secretion form MSCs. However, the role in promoting growth factors such as EGF, HGF, PDGF, and TGF- β is still unclear. Study reported that SIRT1 may be involved in RV enhancing MSCs PDGF secretion [31,32]. PDGF plays a role in each stage of wound healing. PDGF works in orchestra with specific cells to stimulate other growth factors secretion. Levels of PDGF are decreased in chronic wounds. Hence, recombinant human variants of PDGF-BB (Becaplermin) have been successfully applied in diabetic patients and it is the only FDA approved drug for chronic wound treatment [4,9,33,34]. The TGF-B1 is the predominates TGF- β in cutaneous wound healing. In this study, we found that RV at $0.1 \,\mu$ M enhanced the highest secretion of TGF-B1 from MSCs. However, serum deprivation condition promoted the highest secretion of TGF- β 1 among AD-MSCs and AM-MSCs group. Transforming growth factor- β 1 (TGF- β 1) is a multifunctional cytokine contributed in growth and differentiation of MSC while inhibiting growth of most other cell types. TGF-B1 protects against serum deprivation-induced apoptosis of MSCs. In wound healing, TGF- β 1 is important in inflammation, angiogenesis, re-epithelialization, and connective tissue regeneration. This growth factor coordinates the spatio-temporal control of wound healing. In the case of delayed cutaneous ulcer healing, the dysregulation of TGF-B1 activity leads to wound dehiscence, consequently introducing external TGF- $\beta 1$ is one of the alternatives to promote wound healing [4,9,35–37].

As limitation, our study is a lack of full understanding of RV dynamic action on growth factors regulation attributing to growth promotion. The mechanism underlying the dose response on growth factors secretion is unclear and would be of great interest for future studies. Future studies would be needed to fully elicit the potential effect of RV preconditioned MSC-CM on wound healing acceleration.

Conclusion

In summary, RV is a potential natural agent for regulating self-renewal and growth factors secretion of various stem cells. Accordingly, RV can facilitate cell proliferation and wound healing related growth factors secretion. This different effect of RV may be explained by various factors like concentration, time and duration of treatment, culture conditions, as well as the stem cell origin. Our results suggested that 0.1 μ M RV was the most effective concentration to promote secretion of wound healing related growth factors.

Disclosure statement

We have no conflict of interest in this present study.

References

- Posnett J, Gottrup F, Lundgren H, et al. The resource impact of wounds on health-care providers in Europe. J Wound Care. 2009; 18(4):154–161.
- [2] Demidova-Rice TH, Hamblin MR, Herman IM. Acute and impaired wound healing: Pathophysiology and current methods for drug delivery, part 2: role of growth factors in normal and pathological

wound healing: therapeutic potential and methods of f delivery. Adv Skin Wound Care. 2012;25(8):349–370.

- [3] Kiritsi D, Nystrom A. The role of TGFβ in wound healing pathologies. Mech Ageing Dev. 2018;172:51–58.
- [4] Natallya FR, Herwanto N, Prakoeswa C, et al. Effective healing of leprosy chronic plantar ulcers by application of human amniotic membrane stem cell secretome gel. Indian J Dermatol. 2019;64(3): 250.
- [5] Theoret C. Tissue engineering in wound repair: The three "R"srepair, replace, regenerate. Vet Surg. 2009;38(8):905–913.
- [6] Maxson S, Lopez EA, Yoo D, et al. Concise review: role of mesenchymal stem cells in wound repair. Stem Cells Transl Med. 2012; 1(2):142–149.
- [7] Hassan WU, Greiser U, Wang W. Role of adipose-derived stem cells in wound healing. Wound Repair Regen. 2014;22(3):313–325.
- [8] Barrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008; 16(5):585–601.
- [9] Yamakawa S, Hayashida K. Advances in surgical applications of growth factors for wound healing. Burns Trauma. 2019;7:10–13.
- [10] Borena BM, Martens A, Broeckx SY, et al. Regenerative skin wound healing in mammals: state-of-the-art on growth factor and stem cell based treatments. Cell Physiol Biochem. 2015;36(1):1–23.
- [11] Pastar I, Stojadinovic O, Yin NC, et al. Epithelialization in wound healing: a comprehensive review. Adv Wound Care. 2014;3(7): 445–464.
- [12] Kim YJ, Seo DH, Lee SH, et al. Conditioned media from human umbilical cord blood-derived mesenchymal stem cells stimulate rejuvenation function in human skin. Biochem Biophys Rep. 2018; 16:96–102.
- [13] Peltz L, Gomez J, Marquez M, et al. Resveratrol exerts dosage and duration dependent effect on human mesenchymal stem cell development. PLoS One. 2012;7(5):e37162.
- [14] Safaeinejad Z, Nabiuni M, Peymani M, et al. Resveratrol promotes human embryonic stem cells self-renewal by targeting SIRT1-ERK signaling pathway. Eur J Cell Biol. 2017;96(7):665–672.
- [15] Azandeh S, Orazizadeh M, Hashemitabar M, et al. Mixed enzymatic-explant protocol for isolation of mesenchymal stem cells from Wharton's jelly and encapsulation in 3D culture system. JBiSE. 2012;05(10):580–586.
- [16] Palumbo P, Lombardi F, Siragusa G, et al. Methods of isolation, characterization, and expansion of human adipose-derived stem cells (ASCs): an overview. IJMS. 2018;19(7):1897.
- [17] Komaratih E, Rindiastuti Y, Wirohadidjojo YW, Dinaryati A, et al. The resveratrol increase of hepatocyte growth factor (HGF) and epidermal growth factor (EGF) levels in wharton's jelly mesenchymal stem cells (WJ-MSCs) secretome: Toward cell free therapy in dry eye disease (DED). Biochem Cell Arch. 2019;19(2):1–9.
- [18] Yoon DS, Choi Y, Jang Y, et al. SIRT1 directly regulates SOX2 to maintain self-renewal and multipotency in bone marrow-derived mesenchymal stem cells. Stem Cells. 2014;32(12):3219–3231.
- [19] Wang X, Ma S, Meng N, et al. Resveratrol exerts dosage dependent effects on the self-renewal and neural differentiation of hUC-MSCs. Mol Cell. 2016;39(5):418–425.
- [20] Isakson M, de Blacam C, Whelan D, et al. Mesenchymal stem cells and cutaneous wound healing: current evidence and future potential. Stem Cells Int. 2015;2015:831095.
- [21] Sun JY, Zhang Y, Song X, et al. The healing effects of conditioned medium derived from mesenchymal stem cells on radiationinduced skin wounds in rats. Cell Transplant. 2019;28(1):105–115.
- [22] Shafiq M, Jung Y, Kim SH. Insight on stem cell preconditioning and instructive biomaterials to enhance cell adhesion, retention, and engraftment for tissue repair. Biomaterials. 2016;90:85–115.
- [23] Li W, Li K, Wei W, et al. Chemical approaches to stem cell biology and therapeutics. Cell Stem Cell. 2013;13(3):270–283.
- [24] Lv YJ, Yang Y, Sui BD, et al. Resveratrol counteracts bone loss via mitofilin-mediated osteogenic improvement of mesenchymal stem cells in senescence-accelerated mice. Theranostics. 2018;8(9): 2387–2406.

- [25] Kim YS, Lew DH, Tark KC, et al. Effect of recombinant human epidermal growth factor against cutaneous scar formation in murine full-thickness wound healing. J Korean Med Sci. 2010;25(4): 589–596.
- [26] Haase I, Evans R, Pofahl R, et al. Regulation of keratinocyte shape, migration and wound epithelialization by IGF-1- and EGF-dependent signalling pathways. J Cell Sci. 2003;116(Pt 15):3227–3238.
- [27] Zhang R, Yin L, Zhang B, et al. H. Resveratrol improves human umbilical cord-derived mesenchymal stem cells repair for cisplatin-induced acute kidney injury. Cell Death Dis. 2018;9(965): 1–13.
- [28] Galiano RD, Tepper OM, Pelo CR, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol. 2004;164(6):1935–1947.
- [29] Tammela T, Enholm B, Alitalo K, et al. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65(3):550–563.
- [30] Zielins ER, Atashroo DA, Maan ZN, et al. Wound healing: an update. Regen Med. 2014;9(6):817–830.

- [31] Kunhiraman H, Edatt L, Thekkeveedu S, et al. 2-Deoxy glucose modulates expression and biological activity of VEGF in a SIRT-1 dependent mechanism. J Cell Biochem. 2017;118(2):252–262.
- [32] Sun LJ, Yu JW, Shi YG, et al. Hepatitis C virus core protein induces dysfunction of liver sinusoidal endothelial cell by down-regulation of silent information regulator 1. J Med Virol. 2018;90(5):926–935.
- [33] Lian Z, Yin X, Li H, et al. Synergistic effect of bone marrowderived mesenchymal stem cells and platelet-rich plasma in streptozotocin-induced diabetic rats. Ann Dermatol. 2014;26(1):1–10.
- [34] Murphy PS, Evans GR. Advances in wound healing: a review of current wound healing products. Plast Surg Int. 2012;2012:190436
- [35] Anitua E, Alkhraisat MH, Orive G. Perspectives and challenges in regenerative medicine using plasma rich in growth factors. J Control Release. 2012;157(1):29–38.
- [36] Penn JW, Grobbelaar AO, Rolfe KJ. The role of the TGF-beta family in wound healing, burns and scarring: a review. Int J Burns Trauma. 2012;2(1):18–28.
- [37] Papanas N, Maltezos E. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises? Int J Low Extrem Wounds. 2007;6(1):37–53.